Article citationsMore>>

Wang, Y.Y., Gao. J., Gu, G.F., Li, G., Cui, C.Z., Sun, B. and Lou, H.X. (2011) In Situ RBL Receptor Visualisation and Its Mediated Anticancer Activity for Solasodine Rhamnosides. ChemBioChem, 12, 2418-2420.
https://doi.org/10.1002/cbic.201100551

has been cited by the following article:

• TITLE: Combination Treatment with BEC and Cisplatin Synergistically Augments Anticancer Activity and Results in Increased Absolute Survival

  AUTHORS: B. E. Cham

  KEYWORDS: BEC, Solamargine, Cisplatin, Curaderm, Anti-Cancer

  JOURNAL NAME: Journal of Cancer Therapy, Vol.11 No.8, August 18, 2020

  ABSTRACT: Plant-derived BEC with its main component solamargine possesses anticancer activities via its effect on a variety of biological pathways in a wide range of human cancer cells. High cure rates with BEC therapy have been obtained in animals with deadly cancers, and, in humans with terminal cancers promising results have been reported. At a clinical level, optimal concentrations of BEC have been established in a topical cream formulation Curaderm, for effective removal of skin cancers, but optimal concentrations of BEC have not been reported for other cancers. The objective of this study was to determine whether combination therapy of Cisplatin with BEC would result in synergism using cure rates as end points. BEC on its own cures Sarcoma 180 in mice, whereas, Cisplatin on its own has no effect on Sarcoma 180 activity. A combination of BEC and Cisplatin shows synergism, resulting in higher cure rates than BEC and Cisplatin at comparable individual concentrations.